Improved Quality of Life (QOL) with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor T Cell Therapy, Compared with Standard of Care (SOC) Using Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 3 Transform Study

MLA

Jeremy S. Abramson, et al. “Improved Quality of Life (QOL) with Lisocabtagene Maraleucel (Liso-Cel), a CD19-Directed Chimeric Antigen Receptor T Cell Therapy, Compared with Standard of Care (SOC) Using Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 3 Transform Study.” Transplantation and Cellular Therapy, vol. 28, Mar. 2022, pp. S188–89. EBSCOhost, https://doi.org/10.1016/s2666-6367(22)00393-1.

APA

Jeremy S. Abramson, Scott R. Solomon, Jon E. Arnason, Patrick B Johnston, Bertram Glass, Alessandro Crotta, Sandrine Montheard, Alessandro Previtali, Fei Fei Liu, Julia Braverman, Shien Guo, Ling Shi, & Manali Kamdar. (2022). Improved Quality of Life (QOL) with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor T Cell Therapy, Compared with Standard of Care (SOC) Using Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 3 Transform Study. Transplantation and Cellular Therapy, 28, S188–S189. https://doi.org/10.1016/s2666-6367(22)00393-1

Chicago

Jeremy S. Abramson, Scott R. Solomon, Jon E. Arnason, Patrick B Johnston, Bertram Glass, Alessandro Crotta, Sandrine Montheard, et al. 2022. “Improved Quality of Life (QOL) with Lisocabtagene Maraleucel (Liso-Cel), a CD19-Directed Chimeric Antigen Receptor T Cell Therapy, Compared with Standard of Care (SOC) Using Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 3 Transform Study.” Transplantation and Cellular Therapy 28 (March): S188–89. doi:10.1016/s2666-6367(22)00393-1.